A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

NCT ID: NCT02184741

Last Updated: 2022-01-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-03
• Study Completion Date: 2020-09-30

Brief Summary

The present survey was conducted to evaluate the efficacy and safety of GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison to placebo using a multicenter, double-blind, intergroup comparison method.

Detailed Description

Among the patients whose risk factors for recurrent miscarriage are unknown who repeatedly miscarry or patients who repeatedly miscarry despite treatment for risk factors, those who have never given birth and have had four or more miscarriages. Patients were assigned into two groups, GB-0998 or placebo, and received 8 ml/kg body weight of GB-0998 (400 mg/kg body weight) or placebo once a day for 5 days. The primary efficacy endpoint was ongoing pregnancy rate at 22 weeks of gestation (excluding miscarriages associated with fetal chromosomal abnormalities) and one of the secondary endpoint was live birth rate.

Conditions

Recurrent Miscarriage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Infusion of normal saline

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.

GB-0998

Infusion of GB-0998 (Immunoglobulin)

Group Type: EXPERIMENTAL

GB-0998

Intervention Type: DRUG

Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.

Interventions

GB-0998

Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.

Intervention Type: DRUG

Placebo

Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.

Intervention Type: DRUG

Other Intervention Names

Intravenous Immunoglobulin （Venoglobulin®IH，2.5g/50ml）; normal saline

Eligibility Criteria

Inclusion Criteria

1. Patients with primary recurrent miscarriage

2. Patients with a history of at least 4 miscarriages (not including biochemical pregnancy in the count of prior miscarriages)

3. Patients with any of the following risk factors for recurrent miscarriage

【Patients with unknown risk factors】 Patients with normal test results for each of the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype

1. Abnormal uterine morphology

2. Thyroid dysfunction

3. Chromosome abnormality in the couple

4. Positive antiphospholipid antibody

5. Factor XII deficiency

6. Protein S deficiency

7. Protein C deficiency

【Patients determined to have risk factors】 Patients with the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype despite receiving treatment for these factors

1. Abnormal uterine morphology (septate uterus): Patients who have undergone surgery

2. Thyroid dysfunction: Patients receiving medical treatment

3. Incidentally positive antiphospholipid antibody, factor XII deficiency, protein S deficiency, protein C deficiency:Patients receiving combination therapy with aspirin and heparin 4．Regardless of whether or not risk factors are present, patients should have experienced at least 1 a miscarriage of a fetus with normal chromosome karyotype 5．Patients below the age of 42 years at the time of obtaining informed consent 6．Patients who can be admitted for at least the period from the start date of administration of the study drug to the date of examination and assessment 1 week after the start of administration of the study drug 7．Patients who have given written informed consent to participate in this study

Exclusion Criteria

1. Patients with chromosome abnormalities in themselves or their partners that are risk factors for recurrent miscarriage, patients with antiphospholipid syndrome, and patients with incidentally positive antiphospholipid antibody (when the latest test result is positive)

2. Patients in whom complications of diabetes mellitus or impaired glucose tolerance has been identified, but who have not received appropriate treatment for this condition

3. Patients who have received intravenous immunoglobulin therapy as treatment for recurrent miscarriage in the past

4. Patients with a history of stillbirth at 22 weeks of gestation or later

5. Patients receiving treatment for malignant tumor

6. Patients with a history of thromboembolism

7. Patients with a history of shock or hypersensitivity in response to the ingredients of this drug or patients with hereditary fructose intolerance

8. Patients who have been diagnosed with IgA deficiency in the past or patients who have a serum IgA level of <5 mg/dL at laboratory tests at registration

9. Patients who have received another study drug within the period of 12 weeks prior to informed consent or who are currently participating in another clinical trial

10. Patients who are unsuitable for this study for any other reason, in the opinion of a principal investigator or sub-investigators

• Maximum Eligible Age: 41 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Japan Blood Products Organization

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hideto Yamada, Director

Role: PRINCIPAL_INVESTIGATOR

Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital

Shigeru Saito, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Toyama

Locations

Japan Blood Products Organization

Tokyo, , Japan

Countries

Japan

References

Yamada H, Deguchi M, Saito S, Takeshita T, Mitsui M, Saito T, Nagamatsu T, Takakuwa K, Nakatsuka M, Yoneda S, Egashira K, Tachibana M, Matsubara K, Honda R, Fukui A, Tanaka K, Sengoku K, Endo T, Yata H. Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial. EClinicalMedicine. 2022 Jun 29;50:101527. doi: 10.1016/j.eclinm.2022.101527. eCollection 2022 Aug.

Reference Type: DERIVED

PMID: 35795714 (View on PubMed)

Other Identifiers

B211-11

Identifier Type: -

Identifier Source: org_study_id